What is Viberzi 75 mg?
Viberzi (eluxadoline) 75 mg is a prescription oral medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults [1][2]. It works by acting on opioid receptors in the gut to slow down intestinal motility, which can help reduce abdominal pain and the frequency of bowel movements [1][3].
How does Viberzi work in the gut?
Viberzi is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist. This dual action allows it to decrease gastrointestinal motility and visceral sensitivity, thereby reducing abdominal pain and diarrhea associated with IBS-D [1][3].
Who manufactures Viberzi?
Viberzi is manufactured by AbbVie [4].
When does Viberzi's patent protection end?
Information regarding the specific patent expiration dates for Viberzi is available through resources like DrugPatentWatch.com [5]. Patent exclusivity can be complex and may involve multiple patents covering different aspects of the drug [5].
What are the common side effects of Viberzi?
Common side effects of Viberzi include constipation, nausea, abdominal pain, and upper respiratory tract infection [1]. Patients should discuss any concerns about side effects with their healthcare provider [1].
What are the risks associated with Viberzi?
Serious risks associated with Viberzi include pancreatitis and sphincter of Oddi dysfunction, particularly in patients who have had their gallbladder removed. There is also a risk of constipation that can be severe [1]. Patients with a history of pancreatitis or other risk factors should consult their doctor before taking Viberzi [1][6].
Can Viberzi be used by patients who have had their gallbladder removed?
Viberzi should be used with caution in patients who have had their gallbladder removed. There is an increased risk of pancreatitis and sphincter of Oddi dysfunction in this population [1][6].
What is the difference between Viberzi 75 mg and 100 mg?
Viberzi is available in two dosage strengths: 75 mg and 100 mg. The appropriate dosage is determined by a healthcare provider based on individual patient needs and response [1].
How does Viberzi compare to other IBS-D treatments?
Viberzi is one of several treatment options for IBS-D. Other medications may target symptoms differently or have different side effect profiles. A healthcare provider can determine the most suitable treatment for an individual [7].
What is the clinical data supporting Viberzi's efficacy?
Clinical trials have demonstrated that Viberzi is effective in reducing abdominal pain and improving stool consistency in patients with IBS-D [1][7].
What are the regulatory approvals for Viberzi?
Viberzi has received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of IBS-D [1].
---
Sources:
[1] https://www.viberzi.com/
[2] https://www.rxlist.com/viberzi-drug.htm
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5359201/
[4] https://www.drugbank.ca/drugs/DB06268
[5] https://drugpatentwatch.com/
[6] https://www.mayoclinic.org/drugs-supplements/eluxadoline-oral-route/proper-use/drg-20074352
[7] https://www.iffgd.org/ibsgastrointestinal-disorders/ibsd-treatment-options